Lucanix (belagenpumatucel-L) / Activate Immunotherapy - LARVOL DELTA

Identification of anoikis-related genes in heart failure: bioinformatics and experimental validation. (PubMed, Hereditas) - "These findings suggest that Tln1 and TGFβ2 may play important roles in HF development through the regulation of anoikis and may serve as therapeutic targets for HF."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • TGFB1 • TGFB2 • TLN1

An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy (ASCO 2014) - Presentation time: Saturday, May 31; 1:15 PM - 5:00 PM; Abstract #8056; P3, N=532; Sponsor: NovaRx Corporation; NCT00676507; "Although, trial did not meet its predefined end point, a non-statistically significant increase in OS was observed in several subsets of pts who began belagenpumatucel-L within 12 w of the completion of frontline chemotherapy." 

P3 data • Non Small Cell Lung Cancer • Oncology

[Late breaking abstract] A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC) (ESMO-ECCO-ESTRO 2013) - Presentation time: 28 September 2013, 15:15; Abstract# 2; P3, N=532; Sponsor: NovaRx Corporation; NCT00676507; “Median OS was 20.3m with belagenpumatucel-L vs. 17.8m with placebo (HR 0.94, p=0.594). A predefined Cox regression demonstrated that the time elapsed between randomization and the end of frontline chemotherapy had a significant impact on survival outcomes (p=0.002). Other prognostic factors were stage, pretreatment radiation, and histology.”

P3 data • Non Small Cell Lung Cancer